Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive entities : Scynexis, inc. save search
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022
Published: 2022-10-24 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.0%
H: 0.76%
C: -7.11%
ongoing infections positive study fungal infection
SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022
Published: 2022-10-11 (Crawled : 13:20) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -0.39%
H: 12.4%
C: 4.26%
positive study
SCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting
Published: 2022-09-08 (Crawled : 13:20) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.0%
H: 4.93%
C: 2.88%
ongoing research education meeting infections positive study group
SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting
Published: 2022-08-04 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 1.58%
H: 12.84%
C: 7.0%
meeting infections positive study
SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections
Published: 2022-07-19 (Crawled : 13:20) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 4.83%
H: 4.15%
C: -2.3%
women infections positive
SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Published: 2022-05-10 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -7.98%
H: 3.06%
C: 1.02%
ongoing positive phase 3
SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections
Published: 2022-04-22 (Crawled : 16:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -18.99%
H: 2.73%
C: -8.98%
infections positive phase 3 fungal infection
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections
Published: 2022-02-10 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -3.54%
H: 7.45%
C: 4.29%
positive results positive infection phase 3 infections
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022
Published: 2022-02-10 (Crawled : 13:00) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -3.54%
H: 7.45%
C: 4.29%
approval positive results potential positive infection phase 3 submission infections
SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections
Published: 2021-04-30 (Crawled : 12:15) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.95%
H: 3.5%
C: 1.89%
positive injection infections
SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
Published: 2021-03-02 (Crawled : 13:00) - globenewswire.com
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.12%
H: 8.25%
C: 6.43%
positive results ongoing fungal infections positive results phase 3 injection infections fungal infection
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
MGOL 4 | $0.229 -4.18% 13.72% 420K
|
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
BQ | $0.269 1.51% 11.15% 1.1M
|
Consumer Non-Durables
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
MGLD 4 | $1.23 8.85% 7.32% 14K
|
Manufacturing
GRFX | $0.2116 -1.58% 7.28% 40K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.